Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant

Fineline Cube Jun 18, 2026
Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 19.0 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Hopstem Biotechnology Secures FDA Clearance for hNPC01 Neural Progenitor Cell Therapy in Hemorrhagic Stroke Motor Dysfunction

Fineline Cube Jun 18, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026

The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly...

Company Drug

Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia

Fineline Cube Jan 28, 2026

Novartis (NYSE: NVS) announced that Leqvio (inclisiran) has received an additional indication approval from the National...

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026

Apeloa Pharmaceutical Co., Ltd. (SHE: 000739), a China‑based contract development and manufacturing organization (CDMO), announced...

Policy / Regulatory

China Drug Administration Implementation Regulations Set for May 2026 Launch

Fineline Cube Jan 28, 2026

China’s State Council this week issued the Implementation Regulations of the Drug Administration Law, a...

Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Fineline Cube Jan 28, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received National Medical Products Administration (NMPA)...

Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Fineline Cube Jan 28, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-5346, the centerpiece of a USD 1.97 billion...

Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026

IVD Medical Holding Ltd (HKG: 1931), a China‑based in vitro diagnostic specialist, announced the launch...

Company Drug

Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials

Fineline Cube Jan 28, 2026

Betta Pharmaceuticals (SHE: 300558) announced that the National Medical Products Administration (NMPA) has approved the...

Company Drug

Nanjing Leads Biolabs Secures FDA Fast Track for LBL-034 in Multiple Myeloma

Fineline Cube Jan 28, 2026

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that LBL-034, a GPRC5D/CD3 bispecific antibody (BsAb) T‑cell...

Policy / Regulatory

NMPA Suspends Two Indian Pharma APIs Over GMP Violations

Fineline Cube Jan 27, 2026

China’s National Medical Products Administration (NMPA) announced enforcement actions against two India‑based active pharmaceutical ingredient...

Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026

Zhaoke Ophthalmology (HKG: 6622) announced expanded distribution agreements for BRIMOCHOL PF to include Singapore and...

Company Drug

Innovent Biologics Secures FDA Fast Track for IBI3003 Trispecific Antibody in Multiple Myeloma

Fineline Cube Jan 27, 2026

Innovent Biologics, Inc. (HKG: 1801) announced that the U.S. Food and Drug Administration (FDA) has...

Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026

Insilico Medicine (HKG: 3696), a China‑based generative AI‑driven biotech, announced a strategic partnership with Qilu...

Company Deals

Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader

Fineline Cube Jan 27, 2026

Acrobiosystems Co., Ltd. made its initial public offering filing to the Hong Kong Stock Exchange,...

Company Drug

Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline

Fineline Cube Jan 27, 2026

Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong...

Medical Device

Bio-heart Secures Indonesia Approval for Iberis RDN System

Fineline Cube Jan 27, 2026

Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its...

Company Drug

BioArctic Partner Eisai Submits EMA Application for Four-Week Lecanemab Dosing in Alzheimer’s

Fineline Cube Jan 27, 2026

BioArctic AB (OTCMKTS: BRCTF) partner Eisai (TYO: 4523) announced submission of a proposed Marketing Authorisation Variation...

Company Drug

Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy

Fineline Cube Jan 27, 2026

Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients...

Company

ASCP Launches $250K Grants for mCRC Biomarker Testing with Pfizer, ASCO

Fineline Cube Jan 27, 2026

The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer (NYSE: PFE) and with participation...

Company Deals

Boehringer Ingelheim Licenses Simcere’s SIM0709 Bispecific for Inflammatory Bowel Disease

Fineline Cube Jan 27, 2026

Boehringer Ingelheim and Simcere Pharmaceutical Group (HKG: 2096) announced a licensing and collaboration agreement to...

Posts pagination

1 … 70 71 72 … 685

Recent updates

  • Hopstem Biotechnology Secures FDA Clearance for hNPC01 Neural Progenitor Cell Therapy in Hemorrhagic Stroke Motor Dysfunction
  • Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant
  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hopstem Biotechnology Secures FDA Clearance for hNPC01 Neural Progenitor Cell Therapy in Hemorrhagic Stroke Motor Dysfunction

Company Deals

Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.